Slide continues for pSivida, Alimera after FDA rejection


Shares of pSivida Corp. (NSDQ:PSDV) and Alimera Sciences (NSDQ:ALIM) slid today on an FDA rejection of their Iluvien drug-device combination.

The federal watchdog agency said it couldn’t approve Iluvien, a back-of-the-eye implant designed to treat diabetic macular edema, because Alimera hadn’t proven that its benefits outweigh its safety risks. The FDA wants Alimera, which licenses the device from pSivida, to conduct two more clinical studies for Iluvien for DME.

pSivida shares fell 12.0 percent today to $1.40, hitting a 52-week low of $1.36 along the way and adding to the nearly 50 percent lost Friday, after the FDA decision was announced.*

Sign up to get our free newsletters delivered straight to your inbox

“I can only reiterate how surprised and disappointed we were by this news. We have had two other back-of-the-eye products previously approved by the FDA and we were optimistic that the FDA would approve Iluvien for DME,” pSivida CEO Dr. Paul Ashton told analysts on a conference call. “Because we have licensed Iluvien to Alimera, the next steps for Iluvien development in DME in the US will be decided by Alimera, not us. We don’t participate in running the clinical trials or developing the regulatory strategy for the DME program.”

ALIM shares suffered as well, dropping 276 percent Friday and another 5.2 percent today, hitting it’s own 52-week low of $1.39 on the way to a $1.50 close.

Alimera has asked the FDA for a meeting to discuss next steps and is suspending a clinical trial the FDA asked for until at least until that meeting, Alimera CEO Daniel Myers told analysts during a separate call.

“Overall, we were surprised and disappointed with the FDA’s decision,” Myers said. “We are committed to and, with approximately $39 million in cash as of Sept. 30, have the funds for evaluating our options in the U.S. and pursuing approval in Europe.”

Alimera has applied for approval from the U.K., Austria, France, Germany, Italy, Portugal and Spain and expects to hear from EU regulatory authorities in the first half of 2012, Myers said.

pSivida’s Ashton said European approval doesn’t trigger a payment, as with the $25 million it would have been due with an FDA green light. But, like the U.S. deal, EU approval does come with 20 percent royalties on European sales and 33 percent of non-royalty payments from any third-party distribution deals.

The company had $21.3 million in net cash as of Sept. 30, he added, “sufficient to support our clinical and planned operations into at least calendar 2013. As those of you who follow us know, now we are a very frugal company.”

And then there’s a second indication for the Iluvien implant to consider: posterior uveitis. Ashton said the FDA decision on DME doesn’t preclude U.S. approval for the uveitis indication, because the two diseases are so different.

“We will be having a meeting with the FDA shortly to better understand what they will need to see for approval for this insert of posterior uveitis and how the FDA’s decision on DME would affect an application in uveitis,” he said during the call. “Now just to reiterate, we don’t believe that the recent decision on the Iluvien in DME will affect our ability to reference the data directed by Alimera in its DME development program. These data include clinical, non-clinical data, manufacturing and stability data and offers the substantial savings in cost and time and if we proceed to offer this for uveitis. However, we certainly plan to discuss the most efficient use of these data with the FDA if we decide to move forward in uveitis.”

pSivida is also co-developing, along with pFizer (NYSE:PFE), a biodegradable insert designed to treat glaucoma and high intraocular pressure, Ashton added.

“So this product is a different insert, as you are looking at different drugs for a different disease than Iluvien for DME,” he said.

*Correction, Nov. 16, 2011: This article originally mis-stated the percentage value lost by PSDV shares between Nov. 10 and Nov. 11. Return to the corrected sentence.

RSS From Medical Design & Outsourcing

  • Procyrion CEO discusses its life-changing pump designed to heal the heart
    Ben Hertzog is the CEO of Procyrion, a Houston-based company that is developing Aortix, a custom designed pump built around a powerful micro-motor mounted on a set of expandable struts. Aortix is designed to rest and heal the heart by reducing afterload and improving blood flow to vital organs. Unlike other circulatory assist devices that […]
  • U.S. Based Qure Medical Acquires UK-Headquartered Silicone Altimex
    Qure Medical, with corporate headquarters in Twinsburg, Ohio, has acquired UK-headquartered Silicone Altimex, announced Randy Ross, President and CEO of Qure Medical. Financial terms of the agreement were not disclosed. Qure Medical provides integrated elastomer solutions to medical device manufacturers. Silicone Altimex is one of Europe’s leading independent manufacturers of cleanroom-produced silicone tubing components and […]
  • Coatings2Go is issued U.S. Patent for hydrophilic coating
    Coatings2Go, a medical device coating supplier, recently announced its receipt of a patent as it relates to hydrophilic coatings. The U.S. Patent Office has issued to Coatings2Go a patent with a grant date of July 14, 2015: U.S. Patent Number 9,080,061, “Coating Resins And Coatings With Multiple Crosslink Functionalities.” “This new patent is the third […]
  • Herrmann Ultrasonics, Inc. announces its 25 Year Anniversary
    In 1990, Thomas Herrmann, the son of Walter Herrmann, who founded Herrmann Ultraschalltechnik GmbH in 1961, established Herrmann Ultrasonics Inc. in the Chicago area. Hermann Ultrasonics, Inc. is proud to recognize a milestone year in observance of their 25th anniversary. Herrmann Ultrasonics has been focused on providing ultrasonic welding technology for various markets such as […]
  • Consumer Health Applications receive the most attention today, but the future is elsewhere
    Wearables for health fall into a wide range of technologies, functions, use cases and over-arching regulatory frameworks that developers and prospective entrants have to understand in order to effectively compete. Using an underlying taxonomy for human health, we establish a health-focused wearables taxonomy around three major categories—applications, use cases, and form factors—the three areas critical […]
  • Paralyzed men move legs with new non-invasive spinal cord stimulation
    Five men with complete motor paralysis were able to voluntarily generate step-like movements thanks to a new strategy that non-invasively delivers electrical stimulation to their spinal cords, according to a new study funded in part by the National Institutes of Health. The strategy, called transcutaneous stimulation, delivers electrical current to the spinal cord by way […]
  • SCHURTER’s new power entry module offers IP 54 protection with V-Lock cord sets
    SCHURTER is pleased to announce, that its power entry module, series 5707, now offers IP 54 protection with V-Lock cord sets at the power input, in addition to IP 65 protection to the equipment. The sealed module is ideal for use in medical equipment exposed to leaks, drips and spills, as well as equipment subject […]
  • GlobTek presents its latest level VI AC/DC adapter and connverter
    T-43086-WWVV-X.X-Q Model is an addition to GlobTek’s Level VI compliant GT-43086 family and represents GlobTek’s 6 Watt wall plug-in series of AC/DC adapters (power supplies and chargers) with International Interchangeable blades. GlobTek’s changeable input blade system with individual field replaceable input plugs, including: North America and Japan NEMA 1-15P, Australian, UK BS 1363, European CEE […]
  • Sanmina’s familiarity with FDA gets skin treatment product to market fast
    The medical market for cosmetic devices is booming. However, quickly launching new products to meet demand is becoming more challenging because device manufactures face increased regulatory scrutiny. To help meet regulatory requirements, aesthetic and other medical-device OEMs are partnering with electronics manufacturing services (EMS) companies that also offer expertise with the FDA filings necessary to […]
  • Fluid connectors and quick disconnects for IVD equipment from CPC
    Colder Products Company (CPC) offers thousands of tubing connectors, quick disconnects and fittings for smart fluid handling in IVD and analytical equipment. Non-spill connectors speed testing throughput by eliminating drips, preventing air inclusion and increasing operator safety. Panel mount connectors can be added to existing equipment or bottle caps to provide secure, leak-free connections. Puncture […]
  • 310 Watt desktop medical power supply meets efficiency level VI requirements
    Power Partners releases a new 310 Watt medical grade desktop power supply from their PEAMD Series of AC and DC adapters. The 310 Watt unit is packed for ideal performance inside a compact case measuring 7.8 x 4 x 2 in. with a weight of only 3 lbs. The PEAMD310 Series is approved to the latest […]

Leave a Reply